Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- AI stocks lift Wall St as oil falls, Treasury yields decline
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
- Novo Nordisk shares drop as investor event disappoints
Fate Therapeutics (FATE) Misses Q3 EPS by 6c
November 1, 2018 5:03 PM EDTFate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.31), $0.06 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1 million versus the consensus estimate of $2.87 million.
For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.
... More